ABSTRACT OF THE DISCLOSURE

A purified compound and its pharmaceutically acceptable salt that inhibits the binding between the integrin intracellular or cytoplasmic tail polypeptide and Paxillin, a pharmaceutical composition containing that compound or salt and a method of treating a biological function in an animal using that compound or salt are disclosed. The purified compound corresponds in structure to Formula I,



wherein W^1 and W^2, X^1, X^2 and X^3 and Y are defined within.